JP Morgan Chase
FENC icon

JP Morgan Chase’s Fennec Pharmaceuticals FENC Stock Holding History

JP Morgan Chase’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$68.4K Buy
11,859
+2,088
+21% +$16.1K ﹤0.01% 6037
2025
Q4 		$75.2K Sell
9,771
-55
-0.6% -$452 ﹤0.01% 6041
2025
Q3 		$92K Sell
9,826
-1,251
-11% -$10.8K ﹤0.01% 5948
2025
Q2 		$91.9K Sell
11,077
-644
-5% -$4.41K ﹤0.01% 5643
2025
Q1 		$71.4K Buy
11,721
+952
+9% +$6.11K ﹤0.01% 5731
2024
Q4 		$68.1K Buy
10,769
+264
+3% +$1.35K ﹤0.01% 5900
2024
Q3 		$52.5K Buy
10,505
+191
+2% +$1.1K ﹤0.01% 5970
2024
Q2 		$63K Buy
10,314
+491
+5% +$4.08K ﹤0.01% 5759
2024
Q1 		$109K Sell
9,823
-3,276
-25% -$32.9K ﹤0.01% 5634
2023
Q4 		$147K Buy
13,099
+1,266
+11% +$10.5K ﹤0.01% 5552
2023
Q3 		$88.9K Sell
11,833
-2,699
-19% -$22K ﹤0.01% 5552
2023
Q2 		$128K Buy
14,532
+14,462
+20,660% +$120K ﹤0.01% 5345
2023
Q1 		$1K Hold
70
– – ﹤0.01% 6516
2022
Q4 		$1K Hold
70
– – ﹤0.01% 6404
2022
Q3 		$1K Sell
70
-7,665
-99% -$52.6K ﹤0.01% 6320
2022
Q2 		$69K Sell
7,735
-8,631
-53% -$50.1K ﹤0.01% 5557
2022
Q1 		$91K Buy
16,366
+16,296
+23,280% +$82.1K ﹤0.01% 5549
2021
Q4 		$0 Buy
+70
New +$521 ﹤0.01% 6740
2021
Q3 		– Sell
-20,021
Closed -$146K – 6570
2021
Q2 		$146K Sell
20,021
-2,893
-13% -$19.3K ﹤0.01% 5390
2021
Q1 		$142K Buy
22,914
+13,244
+137% +$99.7K ﹤0.01% 5284
2020
Q4 		$72K Buy
9,670
+1,699
+21% +$12.9K ﹤0.01% 5069
2020
Q3 		$48K Buy
7,971
+706
+10% +$4.98K ﹤0.01% 4940
2020
Q2 		$61K Buy
+7,265
New +$54K ﹤0.01% 4759
2019
Q4 		– Sell
-110
Closed -$1K – 5692
2019
Q3 		$1K Buy
+110
New +$485 ﹤0.01% 5649
2019
Q2 		– Sell
-2,831
Closed -$14K – 5822
2019
Q1 		$14K Sell
2,831
-802
-22% -$5.27K ﹤0.01% 5474
2018
Q4 		$23K Buy
3,633
+946
+35% +$6.61K ﹤0.01% 5293
2018
Q3 		$22K Sell
2,687
-35,449
-93% -$329K ﹤0.01% 5404
2018
Q2 		$398K Buy
+38,136
New +$452K ﹤0.01% 4277

Other funds holding FENC

RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCM
Potomac Capital Management New York $115M AUM

JP Morgan Chase's FENC Position: Q1 2026 in Review

JP Morgan Chase increased its Fennec Pharmaceuticals (FENC) stake by 21% in Q1 2026, buying an estimated $16.1K and bringing the position to 11,859 shares worth $68.4K. The position accounts for ﹤0.01% of the portfolio, ranked #6037.

JP Morgan Chase first reported a position in FENC in Q2 2018 and has held it in 28 quarters since. The position peaked at $398K in Q2 2018. 90 funds tracked by Wall St. Rank hold FENC as of Q1 2026.

  • JP Morgan Chase held 11,859 shares of Fennec Pharmaceuticals worth $68.4K as of Q1 2026.
  • JP Morgan Chase bought 2,088 Fennec Pharmaceuticals shares in Q1 2026, an estimated $16.1K.
  • Fennec Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #6037 holding.
  • JP Morgan Chase first reported a position in Fennec Pharmaceuticals in Q2 2018 and has held it in 28 quarters since.
  • JP Morgan Chase's Fennec Pharmaceuticals position peaked at $398K in Q2 2018.
  • 90 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.